It is intended to provide a monoclonal antibody having a growth inhibitory activity against a cell having a human CD20 antigen which is produced by using, as immunogens, a human B cell line expressing the human CD20 antigen and a cell line originating in a non-human animal, which is ...
Anti-CD20 mABs are extensively effective as target therapies in treating cancer indications. These drugs target CD20 antigen on the cancer cells which is not possible in traditional therapies. Increasing research and developments in this field and various affirmative clinical trials are expected to ...
Systemic B-cell depletion and clinical remission can be achieved in non-Hodgkin lymphoma by a human/mouse chimeric monoclonal antibody that specifically reacts with the CD20 antigen (Rituximab). Similar effects could be expected in type II MC. Methods. Six patients, mean age 64.2 years (range:...
The infusion of anti-CD20 monoclonal antibodies promotes a depletion of CD20+B cells within hours, mainly occurring in the liver [34]. Such a depletion reaches the nadir typically after 8 weeks and can be sustained for several weeks to months according to the posology and the features of th...
In a further development, active targeting combines the potential of nanoparticulate systems to carry anticancer drugs with the capacity of the ligand to target specifically malignant cells. More efficient distribution of the drug to tumor tissue, higher efficacy in earlier stages of cancer and higher...
Moreover, the side effect profile of chronicsteroid administration is undesirable due to the multi-systemicactions of these drugs. Recently, it has been reported in theliterature that Rituximab is effective treatment for chronicITP and it has been used at a dose of 375mg/mweekly for upto four...
1. Uchida J.et al.,2004.Mouse CD20 expression and function Int Immunol. 16(1):119-29. 2. Cvetković R.S. & Perry C.M., 2006.Rituximab. Drugs. 66:791-820. 3. Freeman C. L. & Sehn L. H., 2018.A tale of two antibodies: obinutuzumab versus rituximab. Br. J. Haematol. 182...
Objective: To evaluate the preclinical toxicity of a functionally humanized anti-CD20 monoclonal antibody SM09 for cynomolgus monkeys following repeated in... XB Zhou,ZD Li,L Sun,... - 《Chinese Journal of New Drugs》 被引量: 2发表: 2012年 ...
Drugs. 2009;69:1483–512. CAS PubMed Google Scholar Popow I, Leitner J, Grabmeier-Pfistershammer K, Majdic O, Zlabinger GJ, Kundi M, et al. A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations. Am J Transplant. 2013;13:3103...
A randomized, double-blind, efficacy and safety study of PF-05280586 (a rituximab biosimilar) compared with rituximab reference product (MabThera®) in subjects with pre- viously untreated cd20-positive, low-tumor-burden follicular lymphoma (LTB-FL). BioDrugs. 2020;34:171–81. 9. Bag-...